Arcellx, Inc. (ACLX) Stock Analysis

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Fri, April 17, 2026 at 12:30 PM UTC 4 min read

Gilead Sciences has received all necessary regulatory approvals for its acquisition of Arcellx and has extended its tender offer for the company's shares. This development is significant for investors as it indicates Gilead's commitment to expanding its oncology portfolio, potentially enhancing its growth prospects and market position. The successful completion of the acquisition could lead to increased value for shareholders of both companies.

Read full article →

Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom

Tue, April 7, 2026 at 11:08 PM UTC 2 min read

Gilead Sciences has announced strategic collaborations with Tubulis, Ouro, and Arcellx, aimed at enhancing its pipeline of therapies. These partnerships are expected to drive innovation and growth, positioning Gilead for potential breakthroughs in treatment options. For investors, these developments signal Gilead's commitment to expanding its portfolio and could lead to significant advancements in revenue and market presence by 2026.

Read full article →